Completed PHASE4 INTERVENTIONAL 2-arm NCT01613807

Humalog® Mix50/50(tm) as a Treatment for Gestational Diabetes

Phase 4 Humalog® Mix50/50(tm) for the Treatment of Insulin Requiring Gestational Diabetes

Sponsor: Eli Lilly and Company

Conditions Gestational Diabetes Mellitus

Interventions Insulin LISPRO Insulin, Long-Acting and Insulin

Updated 8 times since 2017 Last updated: Jun 7, 2022 Started: Oct 31, 2008 Primary completion: Jun 30, 2010 Completion: Oct 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01613807, this PHASE4 trial focuses on Gestational Diabetes Mellitus and remains completed. Sponsored by Eli Lilly and Company, it has been updated 8 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jul 2022 — Jul 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2022 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 3 earlier versions

Dec 2017 — Jun 2018 [monthly]

Completed PHASE4
Feb 2017 — Dec 2017 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Oct 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eli Lilly and Company
Sansum Diabetes Research Institute

Data source: Sansum Diabetes Research Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.